Modafinil (Off-Label Use)
PharmaceuticalThe medical rating (62) is below the community score (71), as clinical studies show inconsistent effects in non-sleep-deprived individuals [s3, s4], while community users subjectively report strong productivity gains [c1, c2]. The discrepancy reflects the gap between subjective perception and objectively measured cognitive parameters.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Modafinil is well-supported for sleep deprivation and shift-work contexts, but evidence for cognitive enhancement in well-rested healthy individuals is weak and inconsistent — a finding many community users confirm from personal experience. Its 12–15 hour half-life makes late dosing a genuine sleep risk that can quickly negate any benefit. In Germany, modafinil is prescription-only and importing it from non-EU countries is prohibited under §73 AMG. Chronic use leads to tolerance and diminishing returns in a meaningful proportion of users.
Description
Prescription wakefulness-promoting agent used off-label as a cognitive enhancer; evidence for attention and executive functions in healthy individuals is limited [s1, s2].
Modafinil is a eugeroic (wakefulness-promoting agent) officially approved in Germany and the EU only for the treatment of narcolepsy [s11]. In 2010, the EMA recommended removing all other indications (e.g., obstructive sleep apnea, shift work sleep disorder) from the product information [s11]. Off-label, modafinil is used by students, researchers, and biohackers as a cognitive enhancer to increase wakefulness, concentration, and executive functions [s1, s2, s3]. In a systematic review by Battleday & Brem (2015), modafinil showed more consistent effects on complex tasks (planning, decision-making) than on simple reaction time tasks [s2]. However, a series of meta-analyses (Fond et al., 2015; Repantis et al., 2020) found that in non-sleep-deprived healthy individuals, modafinil primarily improves attention, while effects on memory and learning performance are small or inconsistent [s3, s4]. In sleep-deprived individuals, effects on wakefulness, memory, and executive functions are larger and better replicated [s3]. Use as a long-term nootropic is not supported by longitudinal data; chronic users report diminishing efficacy and cognitive impairment with insufficient sleep [s5, c1]. Modafinil affects dopamine, noradrenaline, orexin, histamine, serotonin, glutamate, and GABA systems [s6, s7, s8]. The precise primary mechanism has not yet been conclusively established [s7].
Legal Status (DE)
In Germany, modafinil is a prescription-only medication (Rx) that has not been classified as a controlled narcotic since 2008 and can be prescribed on a standard prescription [s13, s14]. Off-label use as a cognitive enhancer by healthy individuals is not medically approved. Importation from non-EU/EEA countries by mail order is generally prohibited under §73 AMG [s15]. In the USA, modafinil is classified as a Schedule IV Controlled Substance [s12].
Mechanism of Action
Modafinil primarily inhibits the dopamine transporter (DAT) and the noradrenaline transporter (NET), resulting in elevated extracellular catecholamine levels [s6, s8]. This effect is weaker than that of classical psychostimulants (amphetamine, methylphenidate) and does not produce pronounced euphoria [s1, s9]. Elevated dopamine and noradrenaline levels indirectly activate the hypothalamic orexin/hypocretin system, which plays a central role in maintaining wakefulness and arousal [s7, s8]. Additionally, histaminergic neurons in the hypothalamus are activated, stabilizing the wakefulness-promoting effect [s8]. Modafinil increases extracellular glutamate and serotonin while simultaneously reducing GABA levels in specific brain regions [s7, s8]. This combination of mild dopaminergic stimulation and broad activation of arousal-related neurotransmitter systems accounts for the wakefulness and attention effects with lower addiction potential compared to classical stimulants [s1, s9]. The precise contribution of each individual neurotransmitter system to the cognitive effect has not been fully elucidated; orexin and histamine pathways are considered key mediators of the wakefulness effect [s7, s8].
Dosing
Kognitive Leistungssteigerung (Off-Label)
- Dose
- 100–200 mg once daily
- Frequency
- 1× täglich morgens, bei Bedarf (nicht täglich)
- Route
- oral
- Duration
- intermittierend (2–3× pro Woche empfohlen)
- Timing
- Morning, fasted or with a light meal; not after 12:00 noon due to risk of sleep disturbance
- With food
- optional
Narkolepsie (zugelassene Indikation, Vergleichsdosis)
- Dose
- 200 mg once daily
- Frequency
- 1× täglich morgens
- Route
- oral
- Duration
- Dauertherapie unter ärztlicher Aufsicht
- Timing
- Morning
- With food
- optional
FDA approval specifies a maximum of 400 mg/day; clinical evidence shows no consistent additional benefit above 200 mg/day for cognitive enhancement [s10]. Off-label use without medical supervision is not recommended in Germany.
Half-life approximately 12–15 hours; late administration (after 12:00) can significantly disrupt nighttime sleep [s5, s9]. First-time users should start with 100 mg. Dose reduction is required in cases of hepatic impairment [s10].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Kopfschmerzen Very commonly (>10% of treated subjects) documented in clinical studies [s10, s16]. | häufig | leicht |
| Übelkeit Common gastrointestinal adverse effect in clinical studies [s9, s10]. | häufig | leicht |
| Schlaflosigkeit / Einschlafstörungen Wakefulness-promoting effect can disrupt sleep when taken late in the day or at higher doses [s5, s9]. | häufig | leicht |
| Schwindel / Benommenheit Documented by users on sanego.de and in clinical reports [s16, c3]. | gelegentlich | leicht |
| Erhöhter Blutdruck / Tachykardie Modafinil increases noradrenergic tone; monitoring recommended in patients with pre-existing cardiovascular conditions [s9]. | gelegentlich | moderat |
| Psychiatrische Symptome (Halluzinationen, Manie, Aggressivität) Rare but severe reactions documented even in psychiatrically unremarkable individuals at standard doses [s9]. | selten | schwer |
| Schwere Hautreaktionen (Stevens-Johnson-Syndrom, toxische epidermale Nekrolyse) Rare, potentially life-threatening cutaneous reactions; listed as a safety concern in the EMA assessment [s11]. | selten | schwer |
| Appetitlosigkeit / Gewichtsverlust Stimulation of the dopaminergic system can reduce appetite [s6, s9]. | gelegentlich | leicht |
Contraindications
Anaphylaxis and severe cutaneous reactions possible in the presence of hypersensitivity [s9, s11].
FDA labeling does not recommend use in these patients [s9].
Increased noradrenergic tone may exacerbate cardiovascular events; StatPearls recommends caution [s9].
Modafinil can exacerbate psychiatric conditions; StatPearls explicitly warns against use [s9].
No controlled studies in pregnant women; animal studies demonstrated transfer into breast milk; EMA and FDA advise against use [s10, s16].
Slowed metabolism; dose reduction or avoidance required [s10, s16].
Interactions
Synergistic
As a choline precursor, Alpha-GPC provides additional acetylcholine, potentially synergistically enhancing the cortical activation augmented by modafinil. This combination is purported to improve cognitive performance and focus, but is supported only by anecdotal reports to date.
As a precursor to acetylcholine and phosphatidylcholine, citicoline enhances cholinergic neurotransmission and supports neuronal membrane integrity, intended to complement the wakefulness-promoting and cognitive effects of modafinil. Scientifically controlled evidence for this combination is currently lacking.
Ashwagandha (Withania somnifera) acts as an adaptogen and may attenuate the potential increase in anxiety and tension associated with modafinil by reducing cortisol levels and stress axis activity. The purported synergistic effect on cognition and stress resilience is based exclusively on anecdotal reports.
L-theanine can attenuate the stimulating and potentially anxiogenic effects of modafinil by modulating GABAergic activity and inhibiting excitatory glutamate receptors, without fully abolishing its wakefulness-promoting effect. This combination is anecdotally used to reduce side effects such as nervousness and restlessness.
Caffeine, as an adenosine receptor antagonist, complements the dopaminergic effects of modafinil and may further enhance focus and energy. Low doses (50–100 mg) are recommended to avoid overstimulation.
Bacopa monnieri is frequently used in combination with modafinil in nootropic stacks to support memory and neuronal communication. The combination targets complementary cognitive domains.
Choline supplements such as Alpha-GPC may reduce headaches experienced by some users taking modafinil, as modafinil increases acetylcholine turnover in the brain. The combination also supports focus and neuronal membrane integrity.
Rhodiola rosea, as an adaptogen, may improve stress-reducing balance during concurrent modafinil use and mitigate post-duration fatigue. The combination targets complementary mechanisms for mental endurance.
Caution
High caffeine doses (>100 mg) combined with modafinil can lead to overstimulation, increased heart rate, and anxiety. The combination should be initiated with low caffeine amounts.
The combination of modafinil with racetams is discussed in nootropic communities, but carries an increased risk of overstimulation and unpredictable interactions, as both substance classes affect dopaminergic and cholinergic systems. Medical supervision is strongly recommended.
Studies
Tier B — Moderate Evidence
Community Evidence
Top reported benefits
- Enhanced alertness and reduced drowsiness
- Improved concentration and focus during monotonous tasks
- Increased productivity, particularly during sleep deprivation
- Extended work capacity without significant crash
Top reported issues
- Headaches after ingestion
- Sleep disturbances when taken too late in the day
- Diminishing efficacy with chronic use (tolerance)
- Absent or weak effect in individual users
- Dizziness and lightheadedness (particularly after first dose)
Several community users report that modafinil provides little cognitive benefit with adequate sleep and that efficacy diminishes with chronic use [c1]. Chronic users warn of a zombie-like state when combined with sleep deprivation [c1]. A non-negligible proportion of users report no perceptible effect on cognition or wakefulness [c2]. Combinations with other stimulants (kratom, phenibut, benzodiazepines) are discussed in forums but are not medically justifiable [c1].
Scientific Sources
- How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine
Repantis D, Schlattmann P, Laisney O, Heuser I (2020). European NeuropsychopharmacologyALink - The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders
Volkow ND, Fowler JS, Logan J, et al. (2013). Psychopharmacology (Berl)BPMID:23995473DOI - PROVIGIL (modafinil) Tablets [C-IV] Prescribing Information
Cephalon Inc. (2010). FDA / AccessdataALink - European Medicines Agency recommends restricting the use of modafinil
European Medicines Agency (2010). EMA Press ReleaseALink - Is Provigil (modafinil) a controlled substance?
Drugs.com editorial staff (2023). Drugs.comBLink - Modafinil aus der BTM-Pflicht entlassen
Pharmazeutische Zeitung Redaktion (2008). Pharmazeutische ZeitungBLink - Modafinil steht nicht mehr unter BtM-Pflicht – Deutsches Ärzteblatt
Deutsches Ärzteblatt Redaktion (2008). Deutsches ÄrzteblattBLink - Privateinfuhr von Arzneimitteln aus dem Ausland - Regierung von Oberfranken
Regierung von Oberfranken (2023). Regierung von OberfrankenBLink - Modafinil: Wirkung, Anwendungsgebiete, Nebenwirkungen - netDoktor.de
netDoktor Redaktion (2023). netDoktor.deCLink - Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review
Battleday RM, Brem AK (2015). European NeuropsychopharmacologyAPMID:26381811DOI - How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine
Repantis D, Berman SM, Buchkremer G, et al. (2020). European NeuropsychopharmacologyAPMID:32340804DOI - Psychostimulants as cognitive enhancers – the evidence for the use and abuse of smart drugs
Fond G, Micoulaud-Franchi JA, Brunel L, et al. (2015). ACNRBLink - Modafinil's effects on cognition and sleep quality in affectively-stable patients with bipolar disorder: a pilot study
Frye MA, Hayes SE, Ketter TA, et al. (2023). Frontiers in PsychiatryADOI - Modafinil: A Review of Neurochemical Actions and Effects on Cognition
Minzenberg MJ, Carter CS (2008). NeuropsychopharmacologyBPMID:18385579DOI - Functional neuroanatomy of dopaminergic arousal systems: implications for the wake-promoting effect of psychostimulants, with particular reference to modafinil
Schwartz JC, Arrang JM, Garbarg M, et al. (2025). Frontiers in NeuroanatomyBDOI - Modafinil - Wikipedia (Mechanism of Action)
Wikipedia contributors (2024). WikipediaCLink - Modafinil - StatPearls
Siri A, Al-Aqabi M, Hashmi MF, et al. (2024). StatPearls Publishing / NCBI BookshelfBLink
Community Sources
Storage
Unopened
Store at room temperature (15–25 °C), dry and protected from light.
Opened
Keep original packaging tightly closed; protect from moisture.
Notes
Keep out of reach of children. Prescription only – legally available in Germany only with a medical prescription.